Home / Health / New DNA Test Spots Hidden Leukemia Relapse Risk
New DNA Test Spots Hidden Leukemia Relapse Risk
12 Mar
Summary
- Specialized DNA test identifies microscopic cancer traces
- NPM1 mutation detection predicts relapse risk in AML patients
- Test offers personalized monitoring for acute myeloid leukemia
A novel DNA-based test is offering a deeper look into acute myeloid leukemia (AML), identifying microscopic traces of cancer that often evade detection. Published in Bone Marrow Transplantation, recent studies highlight the test's ability to pinpoint measurable residual disease (MRD), crucial for predicting patient outcomes after stem cell transplants.
The research specifically examined the NPM1 gene mutation, present in approximately 30% of adult AML diagnoses. Using advanced next-generation DNA sequencing on 190 patient blood samples, the test proved highly sensitive, detecting the mutation in fewer than 1 in 10,000 cells. Patients with a positive NPM1 signal before transplantation showed a three to four times higher likelihood of cancer recurrence.
This breakthrough aligns with the growing movement towards precision medicine, tailoring treatments based on individual genetic profiles. Senior author Christopher Hourigan emphasized the necessity of robust studies to ensure new technologies are used responsibly. A nationwide study, MEASURE, involving 18 major cancer centers, is currently expanding and validating this research, with results expected by the end of the year.
